Chen Schor

Chen Schor serves as the President and Chief Executive Officer, bringing over 25 years of extensive leadership experience in the global biopharmaceutical sector. He holds an MBA, a B.A. in Biology, and a B.A. in Economics, and is also a Certified Public Accountant. Schor’s career is marked by his strategic leadership in transactions valued at over $8 billion with major companies such as GSK, Amgen, Pfizer, and Merck KGaA. He successfully led the turnaround of Synta Pharmaceuticals, culminating in a reverse merger with Madrigal Pharmaceuticals. Previously, Schor served as Vice President of Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals and was a Partner at Yozma Venture Capital, where he played a crucial role in the foundation and growth of multiple therapeutic companies. Additionally, he holds significant board roles, including being a board member with the Alliance for Cancer Gene Therapy, Chairman of the Board of Carbon Biosciences, and a board member at Karyopharm Therapeutics.